



an Open Access Journal by MDPI

Tumor Biomarkers in Gynecology

Guest Editors:

Dr. Corrado Terranova

Department of Obstetrics and Gynecology, University “Campus Bio-Medico” of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy

Dr. Francesco Plotti

Department of Obstetrics and Gynecology, Campus Bio-Medico University of Rome, 00128 Rome, Italy

Deadline for manuscript submissions:

closed (29 February 2024)

Message from the Guest Editors

Gynecological cancers are frequently found in the female population worldwide. Despite the efforts of scientists in implementing screening and early diagnosis programs, only in cervical cancer have we been able to identify an effective method of prevention.

In relation to ovarian cancer, the literature has analyzed well-known CA125 and HE4, which are historically reliable, but early-stage diagnosis requires the implementation of more precise biomarkers. Attempts are being made to introduce liquid biopsy for early detection to identify promising biomarkers among microRNAs.

Although used for endometrial cancer, the known protein CA-19.9 is imprecise and was surpassed by HE4, whose clinical utility may be limited by the lower sensitivity, but it is strongly related to the prognosis. The new frontier with higher specificity and sensitivity are proteomic biomarkers (i.e., YKL-40, DJ-1) and promising exonal biomarker miRNA (i.e., 21,27 and 223).

New horizons are also being studied in this field, looking for new effective markers on peripheral blood for early diagnosis and risk stratification for the development of breast cancer.



mdpi.com/si/158682



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)